6:41 PM
 | 
Sep 22, 2008
 |  BC Extra  |  Clinical News

Allergy's ragweed vaccine meets Phase III endpoint

Allergy (LSE:AGY) said its Pollinex Quattro Ragweed vaccine met the primary endpoint of a reduction in combined symptom/medication score in the Phase III R301 trial to treat ragweed pollen allergy. Vaccinated patients in the per protocol population had a 12% improvement vs....

Read the full 191 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >